Download presentation
Presentation is loading. Please wait.
Published byGodwin Stephens Modified over 9 years ago
1
Constipation: treatment in primary care, when to refer and novel therapies.... Lee Dvorkin Consultant General, Colorectal & Laparoscopic Surgeon Spire Roding Hospital Department of Surgery – North Middlesex University Hospital
2
The next 20-30 mins An overview Primary care management cIBS Faecal impaction When to refer Novel therapies
3
Constipation 2nd most common GI symptom 3% of population (2 - 34%) 1% have intractable symptoms Often in combination with FI
4
Epidemiology and Cost Constipation is more common in –Women (X3) –> 65 years –Non-whites –Poor socio-economic background Most common treatment is laxatives –3 million people (USA) –> $725 million
5
Constipation A subjective term reported by patients when their bowel habit is perceived to be abnormal Wide variety of symptoms Objective criteria now exist Rome II (Thompson et al., 1999)
6
Rome II Criteria At least 12 weeks in the preceding 12 months, of 2 or more of the following –straining in > 25 % defaecations –hard stools in >25 % defaecations –incomplete evacuation in >25 % defaecations –anorectal obstruction / blockage in >25 % defaecations –digitation >25 % defaecations –<3 defaecations / week
7
Specialists Primary care ~75% non-consulters ~70% female ~30% male ~25% consulters
8
Constipation: Aetiology Aetiology Structural Functional Secondary (systemic) Drugs and Diet Endocrine Metabolic Neurological Primary (bowel problem) Colon or rectum
9
“Primary” Constipation Structural l Cancer l Strictures l Megacolon/rectum H Hirschsprung’s H Idiopathic l Outlet obstruction l Anal stenosis l Rectocele l Prolapse u Functional l c- IBS l Colonic inertia l Iatrogenic (post pelvic surgery) l Evacuatory dysfunction l Rectal hyposensitivity l Anismus l Proctalgia fugax l ‘anal fixators’
10
Treatment: functional constipation Vast majority don’t need referral or Ix unless no response to simple measures Treatment focussed on underlying cause.... –Combination of softener and stimulant –High fibre for slow transit –Suppositories for evacuatory dysfunction –Colonic Irrigation –Bowel retraining / Biofeedback –Novel therapies including surgery
11
cIBS treatment Stress relief Hypnosis/Yoga Mebeverine 135mg tds before meals Laxatives (avoid lactulose) Antidepressants (avoid constipating ones) Diet-wheat exclusion, reduce fibre
12
Faecal Impaction PR Elderly, immobile patients No red flag symptoms Treat with enemas then reassess
13
Bowel-retraining programme Package of care Psychosocial counselling Optimisation of medication / diet/laxatives Pelvic floor co-ordination exercises ‘Biofeedback’ techniques
14
Pelvic floor co-ordination exercises Posture Diaphragmatic breathing Abdominal bracing exercises Balloon expulsion Splinting
15
‘Biofeedback’ Physiological parameter (sphincter pressure) displayed on a screen visible to the patient Patients are re-educated, and learn how to co-ordinate the activity of the pelvic floor and anal sphincters
16
Novel therapies
17
Colectomy/Proctocolectomy for constipation Poor results High complication rates Rectal and small bowel dysmotility reduces effectiveness of colectomy Even stoma unsatisfactory but good results in selected few
18
ACE Good results esp. with neurological disease Intubate stoma with water or osmotic laxative High stoma complication rate
19
Prucalopride NICE approved Women only Failed 2 different laxatives after 6 months If no response after 4 weeks unlikely to work Selective serotonin agonists leads to colonic motility (1-2mg od)
20
Sacral Nerve Stimulation Stimulation of S3 “neuromodulation” effect on ascending pathways, local autonomic system –Locally (sphincter pressures, rectal sensation) –Distant (gut motility) 2 stage procedure –Trial period 3 weeks –Permanent implant
21
Indications Constipation –not NICE approved –Largest study to date, Kamm et al 2010, Gut. –Sig improvement in no of defecations, straining, incomplete emptying and abdo pain –Used in both slow transit and obst defecation –Difficult to achieve complete resolution of symptoms
22
SNS: Problems Expensive –Test box £200, Lead £2000, Battery £8000 Post operative problems –Infection, nerve damage, battery lasts 6-8 years Loss of efficacy over time –Requires regular “re-programming” Pregnancy –Must be switched off during pregnancy –c-section to avoid lead displacement
23
Posterior Tibial Nerve Stimulation 2003 used for FI Neuromodulation of sacral plexus via the posterior tibial nerve Achieved by –Percutaneous –transcutaneous
24
PTNS- Indications Just FI, so far Studies in constipated patients awaited
25
PTNS Cheap equipment costs –Needles £200 –Pads £3 –Stimulator boxes £80
26
Conclusions Simple therapies often effective Tailor treatment to underlying pathophysiology Refer to exclude underlying disease or if simple measures ineffective Avoid surgery!
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.